首页|改良格拉斯哥预后评分在软组织肉瘤术前的应用价值

改良格拉斯哥预后评分在软组织肉瘤术前的应用价值

扫码查看
目的 评价全身炎症反应标志物改良格拉斯哥预后评分(modified Glasgow prognostic score,mGPS)在软组织肉瘤术前的应用价值.方法 回顾分析 2016 年 12 月至 2021 年 12 月,新疆医科大学第一附属医院收治的 51 例软组织肉瘤患者的临床资料.分析术前炎症指标与总生存期(overall survival,OS)之间的关系.结果 组织学分级(G1、G2、G3)P=0.002,临床分期(Ⅰ 期、Ⅱ 期、Ⅲ 期)P=0.035,mGPS(0 分、1 分、2 分)P=0.000 与软组织肉瘤术后 OS 显著相关.而组织学分级(G1、G2、G3)P=0.022,mGPS(0 分、1 分、2 分)P=0.001 是软组织肉瘤患者 OS 的独立预后因子.结论 mGPS 可有效预测软组织肉瘤患者的预后,可引用到肉瘤患者的常规诊断中预测预后.
Application of modified Glasgow prognostic score in soft tissue sarcoma
Objective To evaluate the preoperative value of the modified Glasgow prognostic score(mGPS)of systemic inflammatory response markers in soft tissue sarcoma.Methods The clinical data of 51 soft tissue sarcoma patients admitted to the First Affiliated Hospital of Xinjiang Medical University from December 2016 to December 2021 were reviewed.The relationship between preoperative inflammatory markers and overall survival(OS)was analyzed.Results Histological grade(G1,G2,G3,P=0.002)and clinical stage(stage Ⅰ,stage Ⅱ,stage Ⅲ,P=0.035,mGPS P=0.000)were significantly associated with overall survival after surgery.However,histological grade(P=0.022,mGPS P=0.001)was an independent prognostic factor for overall survival of patients with soft tissue sarcoma.Conclusions mGPS can effectively predict the prognosis of patients with soft tissue sarcoma.mGPS could be incorporated into routine diagnosis to predict prognosis of sarcoma patients.

SarcomaSoft tissue neoplasmsPrognosisGlasgow outcome scale

曹世聪、郭政、王岚松、杨欣、徐磊磊、田征

展开 >

830000 乌鲁木齐,新疆医科大学第一附属医院骨科

肉瘤 软组织肿瘤 预后 格拉斯哥预后评分

2024

中国骨与关节杂志
中国医疗保健国际交流促进会,北京中科康辰骨关节伤病研究所

中国骨与关节杂志

CSTPCD
影响因子:0.665
ISSN:2095-252X
年,卷(期):2024.13(7)